FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamis Pharmaceuticals Skyrockets Amid IND Submission to FDA for Covid-19 Treatment”
Adamis Pharmaceuticals (NASDAQ: ADMP) shot up over 27% in premarket trading after announcing the submission of an Investigational New Drug to the FDA for the use of Tempol.
It is used as a treatment for COVID-19, Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity and the submission of the IND follows a Pre-IND meeting with FDA.
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. In addition to its ZIMHI, naloxone injection product candidate, Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, and asthma. The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States.
For more information, please visit: Adamis Pharmaceuticals
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.